BCL2 and B-cell chronic lymphocytic leukemia: The polymorphism 938C > A within an inhibitory region of the BCL2 promoter has been reported to regulate BCL2 protein expression and to be associated with adverse prognostic features in CLL (shorter overall survival, time to first treatment, disease stage at diagnosis and ZAP-70 status) [82].